-$0.52 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter

Wall Street brokerages forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will announce earnings per share (EPS) of ($0.52) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.64) and the highest estimate coming in at ($0.34). Intellia Therapeutics reported earnings of ($0.61) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.8%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 13th.

On average, analysts expect that Intellia Therapeutics will report full-year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.89). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.56) per share, with EPS estimates ranging from ($3.35) to ($1.18). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Wednesday, October 31st. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Intellia Therapeutics had a negative return on equity of 31.70% and a negative net margin of 308.81%. The business had revenue of $7.41 million for the quarter, compared to analyst estimates of $11.58 million. During the same period last year, the firm posted ($0.44) EPS. Intellia Therapeutics’s quarterly revenue was up 1.2% on a year-over-year basis.

A number of equities analysts have recently commented on the company. Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Wedbush cut Intellia Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $36.00 to $20.00 in a report on Friday, November 2nd. BidaskClub cut Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 2nd. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a report on Wednesday, October 31st. Finally, Credit Suisse Group assumed coverage on Intellia Therapeutics in a report on Monday, October 29th. They set a “neutral” rating and a $24.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $35.50.

Intellia Therapeutics stock opened at $19.34 on Tuesday. Intellia Therapeutics has a 52 week low of $16.33 and a 52 week high of $35.99. The firm has a market cap of $801.09 million, a PE ratio of -10.29 and a beta of 3.87.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Macquarie Group Ltd. acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at about $101,000. Patriot Financial Group Insurance Agency LLC acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at about $116,000. Nikko Asset Management Americas Inc. acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at about $141,000. Legal & General Group Plc increased its stake in shares of Intellia Therapeutics by 75.4% in the second quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock valued at $149,000 after buying an additional 2,333 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Intellia Therapeutics by 519.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,733 shares of the company’s stock valued at $157,000 after buying an additional 4,807 shares during the period. 66.59% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Featured Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply